Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01253668 · ClinicalTrials.gov registry record · Phase 2
Brivanib Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT01253668: Clinical Trial Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT01253668 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01253668, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imaging and molecular features of the tumors can be used to predict response. Approximately 30 people with advanced kidney cancer will be enrolled on this study at the University of Pennsylvania.
Primary Outcome
All patients will be followed through the entire 16-week period and will be given a binary outcome assignment: progressive disease or not.
Interventions
- GENETIC Protein expression analysis
- DRUG Brivanib alaninate
- GENETIC Polymerase chain reaction
- OTHER Iodine I 124 chimeric monoclonal antibody G250
- PROCEDURE Positron emission tomography/computed tomography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-11 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Why NCT01253668 stopped before completion
NCT01253668 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 5 interventions - of which Protein expression analysis is the first listed.
NCT01253668 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01253668 about?
NCT01253668 is a clinical study titled "Brivanib Metastatic Renal Cell Carcinoma". This is a phase II study of an investigational agent, brivanib, in patients with refractory metastatic renal cell carcinoma. This study will evaluate the safety and effectiveness of brivanib in renal cell carcinoma, and explore the activity of this drug in this population to determine whether imagin...
What is the current status of trial NCT01253668?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-11. Estimated completion is 2013-09.
What interventions are being tested in trial NCT01253668?
The interventions under investigation include: Protein expression analysis (GENETIC), Brivanib alaninate (DRUG), Polymerase chain reaction (GENETIC), Iodine I 124 chimeric monoclonal antibody G250 (OTHER), Positron emission tomography/computed tomography (PROCEDURE).
Who is sponsoring clinical trial NCT01253668?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01253668's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia